Evlarco (obicetrapib;ezetimibe)

Where it stands

Evlarco (obicetrapib;ezetimibe), from A. Menarini International Licensing S.A., received a positive CHMP opinion on 23 July 2026. The records list its status as "Opinion" and show no approval date, so the European Commission (EC) has not yet granted a marketing authorisation according to the data provided.

The proposed indication is the treatment of primary hypercholaesterolaemia or mixed dyslipidaemia. The therapeutic areas recorded are hypercholesterolemia and dyslipidemias.

A CHMP positive opinion is a scientific recommendation. It is not itself a marketing authorisation, and the product cannot be marketed in the EU until the EC issues its decision.

Regulatory pathway and designations

The records show no designations for this product. They do not list orphan, PRIME or other special status, and they do not say whether an accelerated assessment or conditional approval route applies. None should be assumed.

A CHMP opinion followed by an EC decision is the sequence of the EU centralised procedure. The EC normally adopts its decision within about 67 days of the opinion. On that basis the records estimate an EC decision around 28 September 2026. This date is a calculated estimate, not an official one, and the actual timing may differ.

The records do not give the legal basis of the application, the assessment timetable or the content of the opinion. These details would normally appear in the CHMP meeting highlights and later in the European Public Assessment Report (EPAR).

Safety and pharmacovigilance

The records do not cover safety data, risk management plan commitments or pharmacovigilance conditions for Evlarco, so no assessment can be made here.

What to watch

The main event is the EC decision, estimated for around 28 September 2026. Treat that date as indicative only until the Commission publishes the decision.

After the decision, the product information and the EPAR should become available. They will show the final approved indication wording, any conditions or additional monitoring, and the safety information. The records contain none of these yet.

Launch timing, pricing and reimbursement are not covered by the records and are decided separately at national level. Nothing can be said about them from this data.